Several past studies assessed SPP1 levels in POAG and primary angle-closure glaucoma with differential findings.42,43 Further characterization of SPP1 levels in humans with progressive optic nerve damage may help in the decision to escalate medical or surgical treatment. The gene discussed is SPP1; the disease is open-angle glaucoma.